Dermapharm Holding SE confirmed earnings guidance for the year 2021. The positive performance in the first half of 2021 lays a good foundation for the further course of the business in 2021. The Board of Management therefore expects that consolidated revenue will continue to grow at between 24% and 26% and thus has confirmed its forecast from April 2021.